Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Overweight 2 Obesity 2 Substance Withdrawal Syndrome 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Melanoma 1 Glioma 1 Glioblastoma 1 Chronic Pain 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 131 Bevacizumab 62 Radiotherapy 52 Magnetic Resonance Spectroscopy 51 Irinotecan 25 Carboplatin 22 Surgical Procedures, Operative 18 Radiation 18 Specimen Handling 17 Carmustine 17 Nivolumab 15 Biopsy 15 Lomustine 14 Aminolevulinic Acid 14 pembrolizumab 12 Radiotherapy, Intensity-Modulated 12 trametinib 11 Radiosurgery 11 Cyclophosphamide 10 Topotecan 9 IL13-PE38 9 Everolimus 9 ribociclib 8 fluorodopa F 18 8 dabrafenib 8 X-Rays 8 Imatinib Mesylate 8 Filgrastim 8 Etoposide 8 Erlotinib Hydrochloride 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡